TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9884259
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir vs. ganciclovir in D+R+ patients
Study: 22905856
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) 50 mg twice daily
Study: 31175909
Drug: brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: brodalumab 210 mg every 2 weeks
Study: 15914987
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel application
Study: 8836612
Drug: Dextromethorphan 240
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan 240 mg
Study: 6662157
Drug: Prizidilol hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol hydrochloride 400‐700 mg once daily (mean 612 mg/day)
Study: 17996212
Drug: Topical levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical levofloxacin (0.5%) four times on the day before surgery + Povidone-iodine (PVI) irrigation
Study: 11195900
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy with irradiation and heating
Study: 11195900
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy without irradiation or heating (placebo group)
Study: 9028977
Drug: Extrapleural intercostal
Normalized name: INTRAPLEURAL MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrapleural intercostal nerve block with intermittent low-dose bupivacaine
Study: 1504638
Drug: Intermittent nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent nicotine (15 mu/kg) via nasal spray
Study: 10464846
Drug: Oral bambuterol
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bambuterol (20 mg nocte)
Study: 31200641
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (CEI)
Study: 26652051
Drug: Progesterone treatment
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone treatment
Study: 20504097
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone therapy (control)
Study: 9706245
Drug: Ganciclovir alone
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir alone or in combination with foscarnet
Study: 9508190
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 100 mg/m2 on day 1 and 5‐FU 1,000 mg/m2/d by continuous infusion for 96 hours (days 1 to 4) without interferon alfa-2b (arm A)
Study: 24326395
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral risperidone
Study: 18054465
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg single oral dose
Study: 23114033
Drug: Fluoride treatment
Normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride treatment
Study: 15199083
Drug: Clozapine alone
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine alone (10 mg single dose)
Study: 24716775
Drug: Self-administered paper
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered paper surveys
Study: 15477366
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 100 mg weekly intramuscularly plus levonorgestrel (LNG) 62.5 or 31.25 microg orally daily
Study: 1936480
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin therapy (6 weeks of intermediate and short‐acting insulin 3 times daily)
Study: 17014060
Drug: Protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors (PIs)
Study: 9443470
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d donepezil
Study: 23284983
Drug: Male drinkers
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Male drinkers consuming ≥ 90 g/d (≈8 drinks/d)
Study: 29889693
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of pneumococcal conjugate vaccine followed by PPS23 vaccine
Study: 12021498
Drug: Influenza vaccines
Normalized name: Influenza vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccines
Study: 10951278
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo UV exposure of human skin with a single dose of 200 mJ/cm2
Study: 15013654
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (both drug and behavioral therapy)
Study: 21982055
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream
Study: 28028369
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon α-2a (0.5 mg daily for 48 weeks)
Study: 11315837
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (metformin + GLP-1)
Study: 15034215
Drug: Raltitrexed 3
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed 3 mg/m2 iv on day 1 and oxaliplatin 70 mg/m2 iv on day 1 and day 8 every 3 weeks
Study: 3356109
Drug: Saline solutions
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solutions (osmolarity range 77-1232 mosmol/l)
Study: 31808297
Drug: Platform-switched implants
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched implants (Group I)
Study: 31808297
Drug: Platform-switched implants
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched implants (Group II)
Study: 1504110
Drug: Alprazolam treatment
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam treatment
Study: 24829
Drug: Corticosteroids combined
Normalized name: combinations of corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids combined with an adrenergic beta-stimulant
Study: 2478368
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug therapy (choline-piracetam)
Study: 11701449
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) administration for 6 days
Study: 24576827
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (1 μg/kg/day)
Study: 22876725
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein based supplement (G1)
Study: 26965560
Drug: Solifenacin 10
Normalized name: solifenacin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 10 mg
Study: 21716130
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 30 mg QD for 7 days
Study: 21716130
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg QD for 7 days
Study: 26029985
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneously every 6 months for 36 months
Study: 2709206
Drug: Nonantibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonantibiotic treatment (Group II)
Study: 2858619
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (azathioprine and prednisolone)
Study: 8866625
Drug: Nebulised fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised fenoterol (2 mg)
Study: 25269598
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g every 24 hours intravenously for 4 days in addition to standard stroke-unit care
Study: 17892635
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch containing rivastigmine (Exelon)
Study: 17892635
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of AD therapies
Study: 11397621
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ceftazidime (3 g/day)
Study: 18394014
Drug: Conventional-dose HT
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose HT (2 mg of 17beta-estradiol and 1 mg of NETA)
Study: 10985613
Drug: Metronidazole 250
Normalized name: metronidazole 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 250 mg 3 times/d
Study: 3882657
Drug: Erythromycin stearate,
Normalized name: Erythromycin Stearate, stearate 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate, 1.5 g
Study: 10634375
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH treatment (0.15 IU/kg x day for 1 week)
Study: 25619124
Drug: Centchroman 30mg
DrugBank: Ormeloxifene (DB13310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centchroman 30mg daily for 12 weeks
Study: 28193605
Drug: Intensive SBP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive SBP treatment (goal of <120 mm Hg)
Study: 10695392
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone (0.5 mg/kg/day)
Study: 16969498
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus cystectomy
Study: 11240946
Drug: Low-dose fluticasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluticasone propionate (FP) 88 microg (2 puffs of 44 microg) twice daily
Study: 9252847
Drug: Secretin stimulation
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secretin stimulation (1 IU/kg intravenous bolus)
Study: 12621276
Drug: Animal-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted therapy (AAT) for 15 minutes
Study: 27914241
Drug: Trebananib plus
Normalized name: Trebananib
DrugBank: Trebananib (DB12056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib plus pegylated liposomal doxorubicin (PLD) 50 mg/m2 once every 4 weeks plus weekly intravenous trebananib 15 mg/kg
Study: 20225606
Drug: Fluorouracil (5-FU)-based
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (5-FU)-based therapy
Study: 6114885
Drug: Quazepam 15
Normalized name: quazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam 15 mg capsules
Study: 31694979
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (2 mg for 8-15 kg; 4 mg for >15 kg)
Study: 10636509
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT)
Study: 21359646
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin 40 mg once daily for 10 ± 4 days
Study: 21150631
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (0.75 ml kg⁻¹) alone
Study: 9411906
Drug: Amitriptyline 100
Normalized name: amitriptyline 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 100 mg
Study: 22359099
Drug: Polyethylene glycol-electrolyte
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-electrolyte solution (PEG)
Study: 3444801
Drug: Alternate day
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate day corticosteroid treatment
Study: 16112244
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus Telmisartan (after 24 weeks of monotherapy for an additional 28 weeks)
Study: 15312391
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy only
Study: 24671488
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment (Tubigrip)
Study: 12622302
Drug: Routine GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine GP treatment + Short-term counselling
Study: 15362959
Drug: Octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide acetate (Sandostatin LAR 10‐30 mg every 4 weeks i.m.)
Study: 19453031
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with omeprazole 10 mg daily (Group A2)
Study: 19453031
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily (Group B)
Study: 7639224
Drug: 10 U
Normalized name: vitamin E 10 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Study: 2562137
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg/day in addition to previous therapy with digitalis and diuretics
Study: 2562137
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of previous therapy (Control)
Study: 19710156
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (182 mg d,l‐alpha‐tocopherol)
Study: 25452446
Drug: Apricoxib 400
Normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricoxib 400 mg once per day with docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 once every 21 days
Study: 9365526
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human granulocyte-colony stimulating factor (rhG-CSF) administered after the first or second chemotherapy cycle
Study: 1770154
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg daily
Study: 7639807
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (9 capsules/day)
Study: 31070845
Drug: Desoximetasone ointment
Normalized name: Desoximetasone Ointment
DrugBank: Desoximetasone (DB00547)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desoximetasone ointment
Study: 3367488
Drug: Cendehill rubella
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cendehill rubella virus vaccine
Study: 29856344
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine groups
Study: 3677542
Drug: Lamotrigine 240
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine 240 mg
Study: 6757152
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg mepindolol plus 12.5 mg hydrochlorothiazide daily
Study: 22175055
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG + 20 mg bisacodyl
Study: 31672177
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after 1-month DAPT
Study: 19483232
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of tranexamic acid
Study: 7402771
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol
Study: 20528839
Drug: Interpleural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural analgesia with a 20-ml loading dose of levo bupivacaine 0.5% followed by a continuous infusion of levobupivacaine 0.125%
Study: 20528839
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia with intravenous morphine patient‐controlled analgesia
Study: 23933905
Drug: Metadoxine extended
Normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metadoxine extended release (ER) 1400 mg/day for 6 weeks
Study: 7880667
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg i.v.
Study: 12590005
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus Kava-Kava 100 mg/day
Study: 2866492
Drug: Terazosin 10
Normalized name: terazosin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 10 mg once daily
Study: 20530322
Drug: Rituximab administered
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab administered at 375 mg/m² weekly for 4 doses
Study: 15545669
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy (CONC RT)
Study: 2650879
Drug: Naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750 mg at the first symptom of the attack, total allowed 1250 mg per 24 h
Study: 30732618
Drug: Liberal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal treatment protocol (3 μg/kg)
Study: 1741738
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (individual or group)
Study: 6807240
Drug: Prostacycline (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacycline (PGI2) infusion at 25 ng/Kg/min before Heparin, then 50 ng/Kg/min during bypass
Study: 27657546
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene Blue Injection
Study: 15654576
Drug: iomeprol 400
Normalized name: Iomeprol 400 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 400 mg iodine/mL
Study: 31631570
Drug: Palliative intent
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative intent treatment
Study: 26166526
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only accepted oral examination for 3 years)
Study: 15498362
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of BMSCs
Study: 10442206
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release tablet (reference substance)
Study: 23035175
Drug: ACE527 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE527 vaccine (10^11 CFU, two doses 21 days apart)
Study: 18031520
Drug: Dronedarone 400
Normalized name: dronedarone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 400 mg bid
Study: 17514629
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (P)
Study: 2090770
Drug: recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant interferon alpha‐2b (rIFN alpha‐2b) 5 MU/m2 thrice weekly for 16 weeks
Study: 28459181
Drug: Advanced Moist
Normalized name: Sunmark Advanced Moisturizer Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced Moist Wound Therapy (Control)
Study: 26683057
Drug: Low-dose-induction oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose-induction oral immunotherapy (OIT) with 3 ml of milk, administered daily after a 5-day hospital build-up period.